NEWS AND EVENTS

InterVenn Biosciences has announced that Andrew Quong has been appointed Chief Executive Officer.  After over a year at InterVenn, Dr. Quong has transitioned to the role of CEO following his position as General Manager and Executive Vice President of Operations at the Company. In his previous role at InterVenn, Andrew led operations, strategic planning, project management, technology transfer and business/partnership development.

Prior to InterVenn, Andrew was the Chief Scientific Officer and Microfluidics Franchise Leader at Standard BioTools (formerly Fluidigm) for over three years. Previously, Andrew served as Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research for nearly six years and has held faculty positions in the Department of Cancer Biology at Thomas Jefferson University and the Department of Oncology at Georgetown University.

Dr. Quong oversaw the operation of shared services for the Kimmel Cancer Center and has served on the editorial boards of Cancer Research and The American Journal of Pathology. Andrew holds a Doctor of Philosophy (PhD) from the University of California, Irvine and a Bachelor of Arts (BA) from the University of California, Berkeley.  “I am honored to lead InterVenn through its next transformative phase,” said Andrew Quong, Ph.D., CEO of InterVenn. “It is an incredibly exciting time for InterVenn as we work to expand our clinical glycoproteomic diagnostic platform and GlycoVision™ RUO service capabilities. I am looking forward to driving continued progress on our innovative glycoproteomic platform development and commercialization with Biopharmaceutical partners.”